Palonosetron versus granisetron in combination with fosaprepitant and dexamethasone for TC therapy in patients with gynecologic gancer

Palonosetron versus granisetron in combination with fosaprepitant and dexamethasone for TC therapy in patients with gynecologic gancer - Antiemetic therapy for TC therapy, phase 3 study.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032860

Enrollment

240

Registered

2018-06-10

Start date

2018-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecologic gancer

Interventions

Palonosetron, fosaprepitant and dexamethasone Granisetron, fosaprepitant and dexamethasone

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female pstienst older than 20 y.o Fistologically confirmed gynecological cancer No history of administration with chemotherapy Scheduled to receive TC regimen

Exclusion criteria

Exclusion criteria: Severe complicatoins or/and brain metastasis History of convulsive disorder Gastrointestinal obstruction

Design outcomes

Primary

Measure	Time frame
The proportion of patients with no vomiting and no nausea	—

Countries

Japan

Contacts

Public ContactSoshi Kusunoki

Faculty of Medicine, Juntendo University Department of Obstetrics and Gynecology

skusuno@juntendo.ac.jp03-3823-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026